Galectin Therapeutics Inc (GALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.87 Million) by net assets ($-130.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Galectin Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Galectin Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Galectin Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galectin Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galectin Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ESAF Small Finance Bank
NSE:ESAFSFB
|
-0.810x |
|
Bluerock Acquisition Corp. Class A Ordinary Shares
NASDAQ:BLRK
|
10.328x |
|
Iris Acquisition Corp II
NYSE:IRAB
|
0.000x |
|
Astral Resources NL
AU:AAR
|
-0.011x |
|
Michlol Finance Ltd
TA:MCLL
|
-0.410x |
|
Alicanto Minerals Ltd
AU:AQI
|
-0.078x |
|
Sparebank 1 Nordvest
OL:SNOR
|
-0.029x |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
0.034x |
Annual Cash Flow Conversion Efficiency for Galectin Therapeutics Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Galectin Therapeutics Inc from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see GALT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-126.19 Million | $-23.88 Million | 0.189x | -53.31% |
| 2024-12-31 | $-103.07 Million | $-41.77 Million | 0.405x | -25.95% |
| 2023-12-31 | $-60.24 Million | $-32.97 Million | 0.547x | -43.27% |
| 2022-12-31 | $-32.19 Million | $-31.06 Million | 0.965x | +110.38% |
| 2021-12-31 | $2.62 Million | $-24.31 Million | -9.292x | -991.22% |
| 2020-12-31 | $24.19 Million | $-20.60 Million | -0.852x | -257.90% |
| 2019-12-31 | $45.59 Million | $-10.85 Million | -0.238x | +83.88% |
| 2018-12-31 | $6.90 Million | $-10.18 Million | -1.476x | +88.92% |
| 2017-12-31 | $1.19 Million | $-15.89 Million | -13.321x | -875.39% |
| 2016-12-31 | $12.02 Million | $-16.41 Million | -1.366x | -101.43% |
| 2015-12-31 | $25.05 Million | $-16.98 Million | -0.678x | -52.64% |
| 2014-12-31 | $27.97 Million | $-12.43 Million | -0.444x | +51.17% |
| 2013-12-31 | $8.23 Million | $-7.48 Million | -0.910x | +3.97% |
| 2012-12-31 | $7.92 Million | $-7.50 Million | -0.947x | +26.61% |
| 2011-12-31 | $4.40 Million | $-5.68 Million | -1.291x | -170.49% |
| 2010-12-31 | $-1.69 Million | $-3.10 Million | 1.831x | +110.44% |
| 2009-12-31 | $-4.47 Million | $-3.89 Million | 0.870x | -91.25% |
| 2008-12-31 | $-469.00K | $-4.67 Million | 9.947x | +430.44% |
| 2007-12-31 | $-2.92 Million | $-5.48 Million | 1.875x | -99.39% |
| 2006-12-31 | $-22.00K | $-6.76 Million | 307.136x | +18060.99% |
| 2005-12-31 | $3.58 Million | $-6.13 Million | -1.710x | -172.85% |
| 2004-12-31 | $10.11 Million | $-6.33 Million | -0.627x | -15.08% |
| 2003-12-31 | $7.62 Million | $-4.15 Million | -0.545x | +70.49% |
| 2002-12-31 | $1.62 Million | $-2.98 Million | -1.845x | -24.69% |
| 2001-12-31 | $1.22 Million | $-1.80 Million | -1.480x | +17.78% |
| 2000-12-31 | $50.00K | $-90.00K | -1.800x | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more